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Abstract
Bacillus anthracis produces a number of extracellular proteases that impact the integrity and yield
of other proteins in the B. anthracis secretome. In this study we show that anthrolysin O (ALO)
and the three anthrax toxin proteins, protective antigen (PA), lethal factor (LF), and edema factor
(EF), produced from the B. anthracis Ames 35 strain (pXO1+, pXO2−), are completely degraded
at the onset of stationary phase due to the action of proteases. An improved Cre-loxP gene
knockout system was used to sequentially delete the genes encoding six proteases (InhA1, InhA2,
camelysin, TasA, NprB, and MmpZ). The role of each protease in degradation of the B. anthracis
toxin components and ALO was demonstrated. Levels of the anthrax toxin components and ALO
in the supernatant of the sporulation defective, pXO1+ A35HMS mutant strain deleted for the six
proteases were significantly increased and remained stable over 24 h. A pXO1-free variant of this
six-protease mutant strain, designated BH460, provides an improved host strain for the preparation
of recombinant proteins. As an example, BH460 was used to produce recombinant EF, which
previously has been difficult to obtain from B. anthracis. The EF protein produced from BH460
had the highest in vivo potency of any EF previously purified from B. anthracis or E. coli hosts.
BH460 is recommended as an effective host strain for recombinant protein production, typically
yielding greater than 10 mg pure protein per liter of culture.
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INTRODUCTION
The Gram-positive bacterial pathogen Bacillus anthracis secretes high levels of the three
proteins that are collectively termed anthrax toxin: protective antigen (PA), edema factor
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(EF), and lethal factor (LF), when grown under conditions thought to mimic those in an
infected animal host. PA is a receptor-binding component which acts to deliver LF and EF
to the cytosol of eukaryotic cells; EF is a calmodulin-dependent adenylate cyclase and LF is
a zinc metalloprotease that cleaves most members of the mitogen-activated protein kinase
kinase family for reviews see [1–4]. Because anthrax pathogenesis is highly dependent on
the actions of the anthrax toxin proteins, vaccine and therapeutic development efforts have
focused on countering toxin action, typically by generating antibodies to PA. The anthrax
vaccine currently licensed in the USA, and developed almost 50 years ago [5], consists of a
partially purified culture supernatant of a protease-deficient strain (V770-NP1-R). PA is the
most abundant protein and the key immunogen in this vaccine. Efforts to produce a
recombinant PA vaccine from B. anthracis by scale-up of an established process [6] appear
to have been hampered by instability of the final product, possibly due to protease
contamination.
While the toxin components can be purified as recombinant proteins from B. anthracis
culture supernatants [6–9], the integrity and yields are limited by the B. anthracis proteolytic
enzymes that are co-secreted. Two extracellular proteases are reported to be abundant in the
B. anthracis secretome: NprB (GBAA_0599) – neutral protease B, a thermolysin-like
enzyme highly homologous to bacillolysins from other Bacillus species, and InhA1
(GBAA_1295) – immune inhibitor A1, a homolog of the immune inhibitors A from other
members of the Bacillus cereus group [10–12]. These two proteases contain zinc-binding
motifs typical for the zincin tribe of metallopeptidases, His-Glu-Xxx-Xxx-His, and belong,
respectively, to the M4 and M6 families of metalloproteases according to the MEROPS
database (http://merops.sanger.ac.uk). A third metalloproptease, camelysin (GBAA_1290),
belonging to the M73 family is found in the secretome of several B. anthracis strains. This
protease is similar to the camelysin of B. cereus, a novel surface metalloprotease [13].
B. anthracis also contains a gene encoding the InhA2 metalloprotease (GBAA_0672, M6
family), although it is not known whether this protease is expressed and secreted. This gene
is an ortholog of the InhA1 described above (68% amino acid identity). Similarly, the
genome of B. anthracis also contains genes encoding TasA (GBAA_1288, M73
superfamily), which is an ortholog of camelysin (60% amino acid identity), and MmpZ
(GBAA_3159, ZnMc superfamily), which is a putative extracellular zinc-dependent matrix
metalloprotease, a member of the metzincin clan of metallopeptidases. This clan is
characterized by an extended zinc-binding motif, His-Glue-Xxx-Xxx-His-Xxx-Xxx-Gly/
Asn-Xxx-Xxx-His/Asp [14].
We hypothesized that secretion of these and other extracellular proteases might significantly
decrease the levels of intact anthrax toxin components in the B. anthracis secretome, so that
disruption of these protease-encoding genes might result in higher protein yields. We
previously inactivated NprB and InhA1 individually and found that NprB deficiency
reduced proteolysis of casein [15], while coagulation of human blood by B. anthracis
required InhA1 for proteolytic activation of prothrombin and factor X [16].
In this report, we describe the adaptation of an improved Cre-loxP system for sequentially
deleting additional protease-encoding genes of B. anthracis. Also, we describe a role of each
protease in degradation of B. anthracis toxin components and another potential virulence
factor, anthrolysin O (ALO) [17]. Our work parallels earlier work to knock out up to eight
proteases from Bacillus subtilis [18,19] so as to produce an improved expression host.
Finally, we suggest that the final B. anthracis strain generated, designated BH460, lacking
six proteases and being sporulation deficient and free of the virulence plasmids, provides an
improved host for production of recombinant proteins. As an example, we show that EF
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produced from BH460 is highly active, whereas previous B. anthracis host strains produced
truncated proteins having low potency.
MATERIALS AND METHODS
Materials
The proteases, oligonucleotide primers, plasmids, and bacterial strains used and analyzed in
this study are listed in Tables 1–4.
Bacterial growth conditions and phenotypic characterization
E. coli strains were grown in Luria-Bertani (LB) broth and used as hosts for cloning. LB
agar was used for selection of transformants [20]. B. anthracis strains were also grown in
LB or FA medium [21]. Antibiotics (Sigma-Aldrich, St. Louis, MO) were added to the
medium when appropriate to give the following final concentrations: ampicillin (Ap), 100
μg/ml (only for E. coli); erythromycin (Em), 400 μg/ml for E. coli and 10 μg/ml for B.
anthracis; spectinomycin (Sp), 150 μg/ml for both E. coli and B. anthracis; kanamycin
(Km), 20 μg/ml (only for B. anthracis). SOC medium (Quality Biologicals, Inc.,
Gaithersburg, MD) was used for outgrowth of transformation mixtures prior to plating on
selective medium. B. anthracis spores were prepared as previously described [22] after
growth on NBY minimal agar (nutrient broth, 8 g/liter; yeast extract, 3 g/liter; MnSO4·H2O,
25 mg/liter; agar, 15 g/liter) at 30 °C for 5 days. Spores and vegetative cells were visualized
with a Nikon Eclipse E600W light microscope (Nikon Instrument Inc., New York).
DNA isolation and manipulation
Preparation of plasmid DNA from E. coli, transformation of E. coli, and recombinant DNA
techniques were carried out by standard procedures [20]. E. coli SCS110 competent cells
were purchased from Stratagene (La Jolla, CA) and E. coli TOP10 competent cells from
Invitrogen (Carlsbad, CA). Recombinant plasmid construction was carried out in E. coli
TOP10. Plasmid DNA from B. anthracis was isolated according to the protocol for the
purification of plasmid DNA from B. subtilis (Qiagen, Valencia, CA). Chromosomal DNA
from B. anthracis was isolated with the Wizard genomic purification kit (Promega,
Madison, WI). B. anthracis was electroporated with unmethylated plasmid DNA isolated
from E. coli SCS110 (dam− dcm−). Electroporation-competent B. anthracis cells were
prepared and transformed as previously described [23]. Restriction enzymes, T4 ligase, and
Antarctic phosphatase were purchased from New England Biolabs (Ipswich, MA). Taq
polymerase, Platinum PCR SuperMix High Fidelity kit and the TOPO TA cloning kit were
from Invitrogen. The pGEM-T Easy Vector system was from Promega. Ready-To-Go PCR
Beads were from GE Healthcare Biosciences Corp. (Piscataway, NJ). For routine PCR
analysis, a single colony was suspended in 200 μl of TE buffer [20] (pH 8.0), heated to 95
°C for 45 s, and then cooled to room temperature. Cellular debris was removed by
centrifugation at 15,000 × g for 10 min. Two microliters of the lysate contained sufficient
template to support PCR. The GeneRuler DNA Ladder Mix from MBI Fermentas (Glen
Burnie, MD) was used to assess DNA fragment length. All constructs were verified by DNA
sequencing and/or restriction enzyme digestion.
Construction of vectors for protease gene inactivation
B. anthracis Ames 35 (pXO1+ pXO2−) (A35) was used for genetic manipulations. The
GenBank database (GenBank Accession No. for the Ames strain is NC_003997) was
analyzed for the identification of target genes and for the corresponding primer design. The
Cre/Lox genetic modification method was adapted to introduce precise genetic knockouts
into B. anthracis genes encoding putative proteases. The general schemes for producing B.
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anthracis mutants using Cre-loxP system were described previously [15,23]. The system
employs vectors we designate generically as pDC, for double-crossover plasmid or pSC, for
single-crossover plasmid. These plasmids are derived from the highly temperature-sensitive
plasmid pHY304 [24], which has permissive and restrictive temperatures of 30 °C and 37
°C, respectively. The pDC vector was used to inactivate the spo0A (GBAA_4394), nprB
(GBAA_0599) [15], inhA1 (GBAA_1295) [16], inhA2 (GBAA_0672) and calY
(GBAA_1290) genes. The pSC vector was used to inactivate the tasA (GBAA_1288) and
mmpZ (GBAA_3159) genes. Both plasmids were used to produce a genomic deletion of the
region from tasA (GBAA_1288) to inhA1 (GBAA_1295). To inactivate the inhA2 gene we
amplified left and right fragments with primer pairs 0672LL/0672LR and 0672RL/0672RR
(Table 2) and inserted them into pDC to produce the pInhA2I plasmid (I at the end of the
proteases gene number means inactivation). To inactivate tasA we amplified left and right
fragments with primer pairs 1288LL/1288LR and 1288RL/1288RR and inserted them into
pSC to produce the pTasALI and pTasARI plasmids. To inactivate the camelysin gene calY
we amplified a DNA fragment overlapping the protease gene with primer pairs 1290L/
1290R and inserted the fragment into the EcoRI-site of pHY304. The internal BglII-
fragment of the calY gene was replaced with a loxP-Ω-sp-loxP cassette flanked by two BglII
sites [15] to create the pCamI plasmid for the gene inactivation. To inactivate the mmpZ
gene, we amplified left and right fragments with primer pairs 3159LL/3159LR and 3159RL/
3159RR and inserted them into pSC to produce pMmpZLI and pMmpZRI plasmids. To
delete the tasA-inhA1 gene cluster we transformed the double protease mutant A35DM
strain (having a LoxP site in the inhA1 gene) with pTasALI and integrated the plasmid into
the genome as described previously [23]. Subsequent transformation of the recombinant
strain with the pCrePAS plasmid eliminated the complete tasA-inhA1 gene cluster and
produced the tetra-protease mutant strain A35TM.
The Cre recombinase-expressing plasmids pCrePAS and pCrePA both have permissive and
restrictive temperatures of 30 °C and 37 °C, respectively, and differ only in the selectable
marker. The pCrePA was used for elimination of DNA regions containing a spectinomycin
resistance cassette located between two similarly oriented loxP sites [15], while pCrePAS
was used in a similar way when the recipient strain did not contain a spectinomycin marker.
In that case, the region to be deleted generally contained an erythromycin resistance gene
along with backbone vector pSC [23]. In both cases, a single loxP site replaced the DNA
region targeted for deletion.
To complement the mutation in the mmpZ gene (A35ΔMmpZ strain) and to restore the
deleted tasA-inhA1 region in the A35TM strain, the 3159CF/3159CR and deltaCF/deltaCR
PCR fragments were inserted into the pSC plasmid. The resulting pMmpZC and pΔTasA-
InhA1C plasmids containing, respectively the intact mmpZ gene and the whole tasA-inhA1
region (C at the end of the proteases gene means complementation), were used for
complementation. Each plasmid was inserted separately into the corresponding mutant by a
single crossover event. During the crossover both the mmPZ gene and whole tasA-inhA1
region were inserted into the genomes of the corresponding mutants. Subsequent elimination
of the vector sequences by Cre recombinase left an intact functional copy of the originally
mutated gene along with an inactive duplicate copy of a fragment of the gene.
Preparation of mutants
The strains used and their relevant characteristics are listed in Table 4. The B. anthracis
NprB, InhA2, TasA, camelysin, InhA1, and MmpZ mutants were constructed in the A35
strain by the replacement of coding sequences with the loxP element as described in the
previous section. The double NprB, InhA1 mutant (A35DM) was created starting from the
A35ΔNprB strain (Table 4) as described before [16]. The tetra-protease mutant, A35TM was
created by deletion of the tasA-inhA1 gene region in the A35DM strain. The A35TM was
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then used for inactivation of the inhA2 and mmpZ genes with plasmids pInhA2I and
pMmpZLI/pMmpZRI. The resulting penta- and hexa-protease mutants were designated
A35PM and A35HM, respectively. The mutant strains were checked at each step to ensure
they had retained the ability to sporulate [25]. To intentionally produce a sporulation-
deficient hexa-protease mutant of A35HM, we inactivated the spo0A (GBAA_4394) gene in
A35HM (Table 4) using the plasmid pSΩL304 [15], obtaining A35HMS. The final protease-
deficient spo0A-negative mutant lacking pXO1 was obtained by repeated passage of the
A35HMS mutant at elevated temperatures to cure pXO1 as described previously [26]. The
final strain was designated B. anthracis BH460 (Table 4).
PCR and sequence analysis of chromosomal modifications
PCR fragments containing loxP sites within mutated genes were amplified and sequenced
using primers listed in Table 2 (0672seqF/0672seqR, 1288seqF/1288seqR, 1290seqF/
1290seqR, 3159seqF/3159seqR). All primers for PCR and sequencing were synthesized by
Operon Biotechnologies, Inc. (Huntsville, AL) or the FDA core facility (Bethesda, MD).
Sequences were determined from both sides of the PCR fragments (Macrogen, Rockville,
MD). For verification of the genomic deletion in the tasA-inhA1 gene area, the region
encompassing the start of tasA gene and the end of inhA1 gene was amplified in the mutant
strains by PCR using the primer pair deltaF/deltaR. The location of the loxP site inside the
PCR fragments was determined by sequencing the fragments.
Western blot analyses
The A35 strain and the mutants were grown at 37 °C in LB in air to analyze B. anthracis
toxin production by Western blot. Overnight cultures were diluted into fresh LB to give
A600 = 0.002 and growth was measured at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 17 and 24 h.
Supernatant samples (6 ml) from each time point were filtered (0.22 μm Millex syringe-
driven filter units, Millipore, Cork, Ireland) and concentrated 10-fold using Amicon Ultra-4
membranes (Millipore). Samples of 5 μl were mixed with 5 μl of 2X Tris-glycine SDS
sample loading buffer (126 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 0.005%
bromphenol blue) (Invitrogen), heated (96 °C, 10 min) and separated on 4–12% Bis-Tris
NuPAGE gels) using NuPAGE MOPS SDS running buffer (Invitrogen). Precision Plus
Protein Standard (All Blue, Bio-Rad, Hercules, CA) was used as molecular weight marker.
Proteins were transferred to MagnaCharge 0.45 μm nylon membranes (Osmonics Inc.,
Minnetonka, MN) using transfer buffer (25 mM Tris, 190 mM glycine, and 20% methanol),
blocked in PBS + 3% skim milk (Difco, Lawrence, KS) for 1 h at room temperature,
followed by three 10 min washes in PBST (PBS + 0.05% Tween20). Membranes were then
incubated with primary antibody diluted in PBS + 1% skim milk overnight at 4 °C. Mouse
monoclonal antibody PA-05-A-G1 Lot#071100-02, 5.9 mg/ml (Naval Medical Research
Center, Biological Defense Research Directorate), for detection of PA, and mouse
monoclonal antibody LF-03-A-G1 Lot# 150900-01, 7.4 mg/ml (NMRC, BDRD), for
detection of LF, were both used at 1:2000. Rabbit antisera for development of blots included
anti-EF serum #5900 (used at 1:8000), anti-camelysin (used at 1:2000), and anti-
recombinant ALO (used at 1:2000). The latter was a kind gift of Richard Rest, Drexel
University College of Medicine, Philadelphia, PA. Appropriate HRP-conjugated secondary
IgGs (KPL, Gaithersburg, MD) were used at 1:10000 followed by development with TMB
(3,3′,5,5′-tetramethylbenzidine) (KPL).
Isolation and purification of EF protein
EF protein with an N-terminal six-histidine tag was expressed from plasmid pProEx-H6-EF
(provided by Wei-Jen Tang) in E. coli BL21(DE3) (Promega) as previously described [27].
EF was expressed in B. anthracis host strains from plasmid pSJ136EFOS, which contains
the EF structural gene in plasmid pYS5 under the control of the PA promoter and signal
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sequence [21]. Host strains BH450 and BH460 containing pSJ136EFOS were grown in FA
medium containing 15 μg/ml of kanamycin at 37 °C for 14 h, largely following procedures
previously used for production of LF [9]. The cultures were cooled, supplemented with 2 μg/
ml of AEBSF [4-(2-Aminoethyl)-benzenesulfonylfluoride·HCl] (US Biological,
Swampscott, MA) and centrifuged at 4550 × g for 30 min. All subsequent steps were
performed at 4 °C. The supernatants were filter sterilized and supplemented with 5 mM
EDTA. Solid ammonium sulfate was added to the supernatants to obtain 40% saturation.
Phenyl-Sepharose Fast Flow (low substitution, GE Healthcare Biosciences Corp.) was added
and supernatants gently mixed in the cold for 1.5 h. The resins were collected on porous
plastic funnels (BelArt Plastics, Pequannock, NJ) and washed with buffer containing 1.5 M
ammonium sulfate, 10 mM Tris-HCl, and 1 mM EDTA (pH 8.0). The EF proteins were
eluted with 0.3 M ammonium sulfate, 10 mM Tris-HCl, and 1 mM EDTA (pH 8.0),
precipitated by adding an additional 30 g ammonium sulfate per 100 ml eluate, and
centrifuged at 18,370 × g for 20 min. The proteins were dissolved and dialyzed against 5
mM HEPES, 0.5 mM EDTA (pH 7.5). The dialyzed samples were applied to a Q-Sepharose
Fast Flow column (GE Healthcare Bio-sciences Corp.) and eluted with a 0–0.5 M NaCl
gradient in 20 mM Tris-HCl, 0.5 mM EDTA (pH 8.0). The EF-containing fractions
identified by SDS-PhastGel analysis were purified on a column of ceramic hydroxyapatite
(Bio-Rad Laboratories, Hercules, CA) with a gradient of 0.02–1.0 M potassium phosphate
containing 0.1 M NaCl (pH 7.0). The fractions containing EF were dialyzed overnight
against 5 mM HEPES and 0.5 mM EDTA, pH 7.5, concentrated as necessary, frozen, and
stored at −80 °C. The molecular mass of purified EF was estimated by liquid
chromatogram-electrospray mass spectrometry using an HP/Agilent 1100 MSD instrument
(Hewlett Packard, Palo Alto, CA) at the NIDDK core facility, Bethesda, MD).
Analysis of EF activity in vitro and in vivo
EF activity was measured by analysis of cAMP production in the RAW264.7 macrophage
cell line. Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal
bovine serum, 2 mM Glutamax, 2 mM HEPES and 50 μg/ml gentamicin (all from
Invitrogen) at 37 °C in 5% CO2. Cells were seeded in 96-well plates 24 h prior to assays. EF
preparations were serially diluted in a constant PA concentration (250 ng/ml) prior to
addition to cells and incubation for 1 h at 37 °C. Total cAMP levels were assessed using the
BioTRAK cAMP enzyme immunoassay kit (GE Healthcare Biosciences Corp.) according to
the manufacturer’s protocol. For analysis of EF potency, groups of five 8-week old female
Balb/cJ mice (Jackson Laboratories, Bar Harbor, ME) were injected via tail vein with EF
preparations combined with an equal dose of PA. Toxin was prepared in sterile PBS. Mice
were monitored for survival for 168 h. All experiments involving animals were performed
under protocols approved by the Animal Care and Use Committee of the National Institute
of Allergy and Infectious Diseases, National Institutes of Health.
RESULTS AND DISCUSSION
Insertion of loxP into protease genes results in truncation of the corresponding proteins
A number of protease genes on the B. anthracis chromosome as well as the spo0A gene were
targeted for inactivation in this study. They are identified here with the gene numbers
assigned by The Institute for Genomic Research (Rockville, Maryland; http://www.tigr.org)
for the “Ames ancestor” strain chromosome (GenBank Accession No. NC_007530, gene
designation GBAA_gene number) [28]. The gene numbers are coincident with the previous
“Ames” strain chromosome (GenBank Accession No. NC_003997, gene designation
BA_gene number) [29]. All genes and proteins inactivated or analyzed in this study are
listed in Table 1 together with corresponding locus tags.
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The inactivation of the nprB and inhA1genes has been previously described [15,16]. In this
study we inactivated the inhA2, tasA, calY, and mmpZ genes. The B. anthracis InhA2 protein
is 96% identical in sequence to the InhA2 protease of Bacillus thuringiensis, which is an
essential virulence factor in that insect pathogen [30]. The tasA gene (GBAA_1288) located
downstream of the putative signal protease gene sipW (GBAA_1287) is only 5 genes
upstream of the InhA1 gene (GBAA_1295). The intervening genes include the calY protease
gene, and the two regulatory genes sinI and sinR (Table 4). The SinI and SinR proteins play
important roles in B. subtilis biofilm formation, acting through protease-dependent processes
[31], while in B. anthracis these proteins regulate secreted proteases [32]. It is interesting
that the genes corresponding to calY and inhA1 are not found in the sinI, sinR region of the
B. subtilis genome. Only the gene for the TasA protease, tasA, is located downstream of
sipW and upstream of sinR and sinI [32]. Both TasA and camelysin are similar to the B.
subtilis TasA protease (36% and 34% sequence identities, respectively). The final gene
selected for inactivation, mmpZ, is reported to form an operon with the downstream gene
(GBAA_3160) [33]. The latter gene encodes a hypothetical secreted protein that is
overproduced in B. anthracis [10]. The absence of the MmpZ protease in the B. anthracis
secretome indicates that this protease could be a target for proteolytic degradation by other
proteases during the stationary phase of growth [10].
The protease genes were inactivated as described in the Materials and Methods section,
followed by sequencing to locate the loxP insertions and infer the corresponding amino acid
changes in the mutated proteins. These are shown in Fig. 1. Typically, the 34-bp loxP
sequence will generate a frameshift and early downstream occurrence of a stop codon in an
alternative reading frame either within the loxP sequence or soon thereafter. Thus, all four
inactivated protease genes encode greatly shortened proteins.
Degradation of proteins in B. anthracis mutants compared with the A35 strain
The levels of the three B. anthracis toxin components, ALO, and camelysin produced by the
B. anthracis mutants were compared to those of the parental A35 strain by Western blot
(Fig. 2). The ten strains were grown in LB at 37 °C over a 24-h period. All strains grew
similarly except the six-protease mutant BH460, which appeared to have a slight lag before
reaching exponential growth phase.
Expression of PA by Ames 35 was detectable starting at 5 h of growth. However, full length
PA (83 kDa) disappeared by the 9th hour of growth due to proteolytic degradation.
Inactivation of the InhA2 protease did not influence production of PA while inactivation of
Spo0A or camelysin actually reduced the half-life of PA by 1–2 h. Inactivation of NprB,
TasA, or MmpZ resulted in increased PA stability up to 10 h. However, PA produced by all
these strains was completely degraded after 17 h. The most stable production of PA among
the single knockout mutants was found in the InhA1 strain. PA was present even at 24 h of
growth with this strain, although some degradation occurred. Surprisingly, the A35DM
double mutant did not demonstrate enhanced PA production. PA degradation generally
began at 6–7 h of growth and continued through 24 h. Strikingly, the A35HMS strain with
six inactivated proteases produced PA with minimal to no degradation during the full 24 h of
growth. Similar analyses were performed to follow production of the other B. anthracis
toxin components, EF and LF. Full length EF (89 kDa) was found to be more vulnerable to
degradation than PA, while LF (90 kDa) was quite stable when produced from most mutant
strains. The levels of full length EF and LF, and the timing of their production, paralleled
what was seen for PA for each mutant strain.
The enhanced breakdown of PA and EF found in the A35DM strain may be explained by
increased production of camelysin in A35DM compared with A35 or the two corresponding
single protease knockouts. Although both the NprB and InhA1 knockout strains had
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increased levels of camelysin, the double mutation produced what seems to be a greater than
additive effect. The camelysin levels produced by the A35DM strain were similar to those
by the Spo0A mutant strain, A35ΔSpo0A. Both strains produced camelysin (19 kDa) that
remained stable over the 24-h period. These observations on post-translational regulation of
camelysin production by several proteases support and expand recently published data
demonstrating that the concentration of InhA1 in culture supernatants is inversely
proportional to the concentration of camelysin [32]. Another interesting finding of our work
was that the global transcriptional regulator Spo0A inhibited camelysin production.
Pflughoeft et al. [32] recently demonstrated that B. anthracis sinR (which was deleted in
those mutants containing the tasA-ihhA1 deletion) also negatively regulates transcription of
camelysin and InhA1, both of which have been suggested to be associated with virulence
[12,34].
Knocking out TasA also increased production of camelysin but to a lesser extent than
elimination of NprB and InhA1. The InhA2 knockout did not result in any change in
camelysin degradation or production when compared to A35, while MmpZ elimination was
actually detrimental to camelysin production. We conclude that inactivation of six proteases
in B. anthracis leads to increased production of full-length toxin proteins in culture
supernatants relative to A35, single, or double protease mutants.
Very low levels of ALO were produced from the A35 strain compared to all the protease
knockouts, with the exception of the InhA2 mutant. The ALO produced by the A35 strain
completely disappeared after 9 hours of growth. Every protease knockout strain showed
increased levels of production or greater stability of ALO (53-kDa band). It is interesting
that ALO breakdown started in A35DM (less in A35ΔInhA1) only after 17 h of growth. A
similar effect was not seen in the A35HMS strain, which allowed accumulation of full
length ALO throughout the 24 h of growth. The ALO gene is under control of a PlcR-
dependent promoter, so that the truncation of the PlcR protein in B. anthracis is expected to
greatly limit ALO synthesis, along with all the other PlcR-dependent proteins [35]. The fact
that ALO can be observed in several of the protease-deficient mutants implies that previous
reports of low ALO production may be attributed, at least in part, to its degradation rather
than to low expression. Camelysin overexpression did not influence ALO production,
indicating that this toxin is not a target for camelysin. Taken together, the results
demonstrate the involvement of multiple proteases in controlling the accumulation of
extracellular proteins in B. anthracis.
Complementation of mutations restores proteolytic activity
To verify that the changes observed above were due to the intended gene knockouts rather
than to unrecognized second-site mutations, we complemented several mutants. To
complement the mmpZ mutation, the A35ΔMmpZ strain was transformed with pMmpZC.
This plasmid undergoes a single crossover to insert the full length, wild type mmpZ gene
next to the mutated one. The pSC vector was eliminated by Cre-recombinase treatment as
described previously [23]. The presence of the intact mmpZ gene in A35MmpZC was
confirmed by PCR and sequencing. Western blot analysis of LF production from
A35ΔMmpZC (Fig. 3A) over 24 h indicated that proteolytic activity was restored to levels
similar to that of A35 (Fig. 2). To restore the large tasA-inhA1deletion in the genome of the
A35TM strain, we transformed with the plasmid pΔTasA-InhA1C (containing the entire
tasA-inhA1 region) and followed steps similar to what was described above. Analysis of
ALO production from the complemented strain verified restoration of proteolytic activity
(Fig. 3B). Complementation of the A35ΔInhA2 strain, and restoration of the InhA2 protease
in the same manner, however, did not result in any difference in secreted proteins (data not
shown).
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All the studies described above were done in derivatives of Ames 35, where the toxin
proteins are encoded on the large virulence plasmid pXO1. Production of the toxin proteins
and secreted proteases in these strains is highly dependent on the growth medium. In
particular, the production of the three toxin proteins and certain proteases is greatly
enhanced by the addition of bicarbonate [11,33,36]. Thus, it is likely that growth in certain
media could produce higher concentrations of both proteases and substrates (e.g., PA, LF,
EF, etc.) and this could lead to even greater degradation than observed here.
Bacillus host strains are widely used in biotechnological processes, and avirulent B.
anthracis strains have been used in this laboratory for a number of years to produce PA and
LF [7,9,37]. However, these strains have not been useful as generic hosts for recombinant
protein production due to the secreted proteases demonstrated by the work presented above.
Our successful elimination of many of the most abundant proteases suggested that the
resulting strains could have value as protein expression hosts. To create an optimal host, we
further modified the A35HMS strain by curing it of plasmid pXO1. The resulting strain,
designated BH460, is non-toxigenic, and can be considered innocuous since it lacks the
major virulence factors of B. anthracis. The permanent deletion of the spoOA gene assures
that the strain dies rapidly at the end of exponential growth, eliminating concerns regarding
laboratory contamination.
B. anthracis strain BH460 produces full-length EF protein
Production of EF from B. anthracis hosts has previously been difficult because this protein
is more susceptible to proteolytic degradation than are PA and LF. The plasmid
pSJ136EFOS encodes the mature EF protein with its native N-terminus (thus, the “OS” for
original sequence) fused to the PA signal sequence and under the control of the PA
promoter. This plasmid is otherwise similar to the plasmids pYS5 and pSJ115 that are
routinely used in this laboratory to produce PA and LF, respectively. Protein purified from
the transformant BH460(pSJ136EFOS) was compared to a preparation made in a similar
way from the single protease mutant host BH450, and to a His6-tagged EF protein purified
from E. coli [27], the latter being the type of material used in previous toxicity analyses
reported by our lab [38]. SDS-PAGE profiles of the recombinant EF proteins are shown in
Fig. 4A. The EF produced from BH460 appeared to be slightly less degraded than that
isolated from BH450. This finding was confirmed by mass-spectrometry analyses (Fig. 4B).
The molecular mass of the recombinant protein isolated from BH460 (88,820 Da) compared
well with the theoretical molecular weight for EF (88,822 Da), differing by 2 Da, which is
within the instrumental error. A second species was found that had a lower mass (88,687
Da) consistent with loss of the N-terminal methionine. These two protein species were
present in about equal amounts (47% for the larger, 53% for the smaller). Mass spectra of
the EF produced from BH450 showed degradation as indicated by losses of 1495.7 and
2455.7 Da, resulting in proteins of 87,326 and 86,366 Da, found with similar abundances of
54% and 46%, respectively (Fig. 4C). EF purified from E. coli was monomorphic, with a
mass of 89,995 Da, differing by only 6 Da from the theoretical molecular weight (89,989
Da, Fig. 4C). These results clearly demonstrate production of full length EF from BH460
compared to the truncated proteins made by BH450.
Activity of EF produced from B. anthracis protease mutants
As noted above, recombinant EF has previously been difficult to produce from B. anthracis
host strains transduced with plasmids such as pSJ136. Furthermore, the EF that was obtained
either from B. anthracis Sterne strain culture supernatant [39] or E. coli [27] consistently
had higher potency in inducing cAMP production in cultured cells or lethality to mice than
EF produced from B. anthracis (data not shown). In fact, no previous recombinant EF
preparations from B. anthracis have been lethal to mice even when injected in doses as high
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as 100 μg (combined with equimolar PA) (data not shown). The ES-MS analyses shown in
Fig. 4 suggest that the low potency of previous B. anthracis-derived EF preparations could
be due to degradation. Consistent with prior results, the BH450-derived EF displayed an
extremely low level of specific activity and was not lethal for mice (Fig. 5A and 5B).
However, the recombinant EF purified from the BH460 culture supernatant had a specific
activity exceeding that of highly active E. coli BL21(DE3)-derived EF (Fig. 5A). Similarly,
when injected with equal doses of PA, recombinant EF prepared from BH460 was lethal to
animals at the 25 μg dose, whereas this dose of E. coli-derived EF had minimal effect (Fig.
5B). EF purified from BH450 was not lethal at 50 μg (Fig. 5B) and even at doses up to 100
μg (data not shown). Thus, the BH460 strain, which produces 5–7 mg of EF per liter of
culture, allows for the first time the purification of substantial amounts of highly active EF
from B. anthracis. Because other proteins purified in the same way from B. anthracis have
consistently been free of endotoxin, use of these EF preparations also eliminates concerns
regarding endotoxin-mediated cAMP co-signaling associated with E. coli-derived
preparations. The BH460 strain has also proven very useful for expression of a variety of
other proteins, typically yielding in excess of 10 mg of final pure protein per liter of culture
(data not shown), as will be reported in separate reports on proteins produced in this system.
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Fig. 1. Sequences of truncated and inactivated B. anthracis proteases
Protease genes were inactivated using a procedure that results in the insertion of the 34-bp
pair loxP sequence (underlined in the nucleotide sequences) flanked by several endonuclease
restriction sites (not indicated). The large region between the TasA and InhA1 genes was
replaced by a loxP sequence using the same procedure. For each protease, the amino acid
and nucleotide sequences shown in bold in the upper section identify the final three amino
acids retained from the original protease. The amino acid sequences following this are
nonsense and/or out of frame translations encoded by the restriction sites and loxP
sequences; translation terminates at the codons indicated by asterisks. The bottom sections
for each gene show the entire amino acid sequences (including signal sequences) for each of
the first four proteases. The frame shifts that occur following the three amino acids shown in
the upper sections cause only the underlined portions of the original amino acid sequences to
be translated. In the InhA2 and MmpZ amino acid sequences, the two identical zinc-binding
active site sequences (HEFGH) are shown in bold. For the large TasA-InhA1 deletion,
truncation of the TasA protein occurs as in the single TasA deletion shown above. The DNA
sequence deleted extends to and includes that encoding the first 402 amino acids of InhA1
(not indicated). The remaining DNA begins with sequences that correspond to the last 393
amino acids of InhA1, which begins with the sequence IMSGGS (dashed underlining).
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Fig. 2. Growth curves and PA, EF, LF, ALO, and camelysin production analyses
Growth curves in LB medium are shown for ten B. anthracis strains over 24 h. Western blot
analyses of PA, LF, EF, ALO, and camelysin at various time points are shown for each
strain. The most slowly migrating band in each set of blots corresponds to the full-length
proteins: PA (83 kDa), EF (89 kDa), LF (90 kDa), ALO (53 kDa), and camelysin (19 kDa).
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Fig. 3. LF and ALO production by mutated and complemented strains
Western blot analyses are shown of (A) LF production by A35ΔMmpZ compared to
A35ΔMmpZC and (B) ALO production by A35TM compared to A35TMC. Numbers on the
top of each lane indicate time in hours at which samples were taken.
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Fig. 4. Comparison of EF proteins purified from either E. coli BL21(DE3) or B. anthracis BH450
and BH460 strains
A) SDS-PAGE analysis of the EF proteins. M – molecular mass markers (Fermentas, Page
Ruler Unstained Protein Ladder). (B) Electron Spray Ionization – Mass Spectra (ESI-MS) of
the EF samples from panel A. Y axis represents relative abundance and X axis represents
mass/charge ratio (m/z). C) Comparison of the experimental molecular masses of the EF
samples extrapolated from ESI-MS data to the molecular masses calculated from the amino
acid sequences. Relative abundances of the resulting components from the ESI-MS data are
shown in parentheses. Final line shows differences between experimental and calculated
masses.
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Fig. 5. EF activity analyses
A) cAMP production by different EF preparations was measured following treatment of
RAW264.7 cells for 1 h with a range of EF concentrations and a set PA concentration (250
ng/ml). B) Potency of EF prepared from BH460 was compared to EF prepared from BH450
or from E. coli BL21(DE3) in Balb/cJ mice challenged with either 25 μg EF + 25 μg PA (for
EF made from BH450, BH460, or E. coli) or 50 μg EF+ 50 μg PA (for EF made from
BH450 only).
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TABLE 1
B. anthracis Ames ancestor strain genes inactivated or analyzed in this study.
Protein Gene Function/Name Locus Tag
NprB nprB metallopeptidase GBAA_0599
InhA2 inhA2 metallopeptidase GBAA_0672
TasA tasA metallopeptidase GBAA_1288
Camelysin calY metallopeptidase GBAA_1290
SinI sinI regulatory protein GBAA_1292
SinR sinR regulatory protein GBAA_1293
InhA1 inhA1 metallopeptidase GBAA_1295
MmpZ mmpZ metallopeptidase GBAA_3159
ALO alo Thiol-activated cytolysin (anthrolysin) GBAA_3355
Spo0A spo0A sporulation regulator GBAA_4394
EF cya edema factor GBAA_pXO1_0142
PA pag protective antigen GBAA_pXO1_0164
LF lef lethal factor GBAA_pXO1_0172
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TABLE 2
Primers used in this study
Primer Sequence a (5′-3′) (location) Relevant property Site
0672LL GCTCGAGCGGATGTACATCTGTAATGAGT Primer pair to amplify left fragment of inhA2gene to
clone it into pDC
XhoI
0672LR GGATATCTTGAACGATGTGACCAAATG EcoRV
0672RL GCCCGGGCCTGTCGAAGCTTGGTCATT Primer pair to amplify right fragment of inhA2 gene to
clone it into pDC
SmaI
0672RR GCCGCGGTTTGCATACCTGTGTTACCG SacII
0672seqF GGTCAAGAAGCTGGTGGAGGTA
Primer pair to verify inhA2gene disruption
0672seqR TCTGTTCCTGCAATTTTCCC
1288LL GCTCGAGTAATTTGGAAGGTGATTAGC Primer pair to amplify left fragment of tasA gene to clone
it into pSC
XhoI
1288LR GCCCGGGTTCACATCTTCTACATTGTAAT SmaI
1288RL GACTAGTAACAATCGTAAAAGAAACAGCG Primer pair to amplify right fragment of tasA gene to
clone it into pSC
SpeI
1288RR GGAGCTCTATCGATCGCCTGTAAATTC SacI
1288seqF GGGGATATGGACATGACTTT
Primer pair to verify tasA gene disruption
1288seqR CAGTAAGTGTGTCACCCTTC
1290L GAGAAGATAGCTGCTGAGAG
Primer pair to amplify calY gene to clone it into pDC
1290R TAGAGGGAGTTTAATGGGGA
1290seqF GAAATTGCGCAAAAAGAT
Primer pair to verify calY gene disruption
1290seqR AGAGCCATTCCAGAACGC
3159LL GCTCGAGGGGTAATAACTTTCAATTAATAC Primer pair to amplify left fragment of mmpZ gene to
clone it into pSC
XhoI
3159LR GGATATCGAAAAAACAAACACAGTACC EcoRV
3159RL GCCCGGGGGTTGGCAAGCTGCCGATTC Primer pair to amplify right fragment of mmpZ gene to
clone it into pSC
SmaI
3159RR GCCGCGGCGAATGGTTCAATTGCTCCG SacII
3159seqF GGTACTGTGTTTGTTTTTTC
Primer pair to verify mmpZ gene disruption
3159seqR GAATCGGCAGCTTGCCAACC
3159CF CCTCGAGTTTCATTTTTGAAGTCTTCTTC
Primer pair to complement mmpZ gene disruption
XhoI
3159CR CACTAGTCAGCGAAACGATGATTGATTTT SpeI
deltaF TCCGATTAGGAAGTTGACAA
Primer pair to verify deletion of tasA-inhA1 region
deltaR CAGTTACCACCAATTGTTTT
deltaCF CCTCGAGTTTTCTTATTGCATTTCTAATGTGTTCG
Primer pair to complement tasA-inhA1 region deletion
XhoI
deltaCR CCCGCGGTTAGCGATATAAGCGAACAG SacII
a
Restriction enzyme recognition sites are underlined.
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TABLE 3
Plasmids used in this study
Plasmid Relevant characteristic(s)a Source or reference
pHY304 Contains EmR gene and strongly temperature-sensitive replicon for both E. coli and gram-positive
bacteria; EmR in both E. coli and B. anthracis
[24]
pDC Ω-sp cassette flanked by two similarly oriented loxP sites and two external multiple restriction
sites (single XhoI, SalI, and EcoRV upstream of first loxP and single PstI, XmaI and SacII
downstream of second loxP) inserted into pHY304
[15]
pSC Plasmid used for single crossovers in B. anthracis. ApR in E. coli; EmR both in E. coli and B.
anthracis
[23]
pInhA2I pDC with loxP-Ω-sp-loxP flanked 3′ and 5′ by inhA2 gene sequences This work
pTasALI pSC containing tasA fragment amplified with primer pair 1288LL/1288LR This work
pTasARI pSC containing tasA fragment amplified with primer pair 1288RL/1288RR This work
pCamI pHY304 with loxP-Ω-sp-loxP flanked 3′ and 5′ by calY gene sequences This work
pMmpZLI pSC containing mmpZ fragment amplified with primer pair 3159LL/3159LR This work
pMmpZRI pSC containing mmpZ fragment amplified with primer pair 3159RL/3159RR This work
pCrePA Contains cre gene and strongly temperature-sensitive replicon for both E. coli and gram-positive
bacteria; EmR in both E. coli and B. anthracis
[15]
pCrePAS Contains cre gene and strongly temperature-sensitive replicon for both E. coli and gram-positive
bacteria; SpR in both E. coli and B. anthracis
[23]
pMmpZC pSC with 3159F/3159R PCR fragment containing entire mmpZ gene This work
pΔTasA-InhA1C pSC with deltaCF/deltaCR fragment containing entire tasA-inhA1 DNA region This work
pS L304 pDC with loxP-Ω-sp-loxP flanked 3′ and 5′ by spo0A sequences [15]
pSJ136EFOS Contains B. anthracis cya gene instead of the lef gene in pSJ115 [9] This work
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TABLE 4
Bacterial strains used in this study.
Strain Relevant characteristic(s)a Source or reference
A33 B. anthracis Ames 33 strain (pXO1− pXO2−) [26]
A35 B. anthracis Ames 35 strain (pXO1+ pXO2−) [15]
A35ΔSpo0A spo0A knockout containing one loxP site, previous name of this strain is SΩL35 [15]
A35ΔNprB nprB knockout containing one loxP site [15]
A35ΔInhA2 inhA2 knockout containing one loxP site This work
A35ΔTasA tasA knockout containing one loxP site This work
A35ΔCam calY knockout containing one loxP site This work
A35ΔInhA1 inhA1 knockout containing one loxP site [16]
A35ΔMmpZ mmpZ knockout containing one loxP site This work
A35ΔmmpZC A35ΔMmpZ complemented in situ by insertion of native mmpZ gene This work
A35DM Ames 35 double mutant with nprB and inhA1 knockouts; each gene contains one loxP site This work
A35TM Ames 35 tetra-protease mutant; has nprB knockout containing one loxP site and deleted DNA region
including tasA, calY, sinI, sinR, and inhA1 genes
This work
A35TMC A35TM with tasA-inhA1 deletion restored in situ by insertion of native DNA region including tasA,
calY, sinI, sinR, and inhA1 genes
This work
A35PM Ames 35 penta-protease mutant; 35TM with inhA2 knockout containing one loxP site; total of 3 loxP
sites in chromosome
This work
A35HM Ames 35 hexa-protease mutant: A35PM with mmpZ knockout containing one loxP site; total of 4
loxP sites in chromosome
This work
A35HMS A35HM with spo0A knockout containing one loxP site; total of 5 loxP sites in chromosome This work
BH460 A35HMS cured of pXO1 This work
BH450 A33; nprB and spo0A knockouts, residual loxP sites in both nprB and spo0A genes; strain was
previously named MSLL33
[15]
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